ALK and adenocarcinoma: It might due to the high prevalence of adenocarcinoma (89.6%) in this cohort, which is consistent with a previous report where adenocarcinoma accounts for most cases (85.3%) of ALK-rearranged NSCLC (Barlesi et al., 2016).